問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Cardiovascular Diseases

Division of General Internal Medicine

Division of Infectious Disease

更新時間：2023-09-19

許志新Hsu, Chih-Hsin
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

Recruiting Trial

19Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

許志新

List

30Cases

2025-03-01 - 2032-12-31

Phase II

Active
An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept (MK-7962) Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care

  • Condition/Disease

    Pulmonary Arterial Hypertension Intervention / Treatment

  • Test Drug

    Freeze-dried injection

Participate Sites
3Sites

Recruiting3Sites

2025-09-15 - 2031-12-31

Phase III

Active
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)

  • Condition/Disease

    Pulmonary Arterial Hypertension

  • Test Drug

    Injectables

Participate Sites
2Sites

Recruiting2Sites

2025-12-28 - 2031-12-31

Phase III

Not yet recruiting
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (WHO Group 3)

  • Condition/Disease

    Pulmonary Hypertension Due to Lung Disease (Disorder)

  • Test Drug

    Inhalation suspensions

Participate Sites
5Sites

Recruiting5Sites

2023-12-08 - 2024-09-30

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-05-08 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-08-30 - 2024-12-17

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2021-05-01 - 2025-12-31

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting12Sites

Terminated1Sites

2024-11-01 - 2028-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-11-01 - 2025-03-12

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2022-06-01 - 2026-02-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB